The Skinny on GLP-1s for Healthcare Industry Risks

Placing You First Insurance Podcast by CRC Group

Ever wondered how the latest advancements in GLP-1 medications are revolutionizing the treatment of diabetes and obesity? Join us for an insightful conversation with healthcare brokers Scott Scheiblin and Chip Wenges as they unravel the complexities and opportunities these groundbreaking drugs bring to healthcare providers. You'll discover the hidden pitfalls of improper prescribing practices, the looming threat of regulatory scrutiny over compounded medications, and the challenges posed by insurers limiting coverage to branded versions. As the demand for GLP-1s skyrockets, we discuss the implications and potential repercussions that could follow.

Visit REDYIndex.com for critical pricing analysis and a snapshot of the marketplace.

Do you want to take your career to the next level? Join #TeamCRC to get access to best-in-class tools, data, exclusive programs, and more! Send your resume to [e-mail] today!

Kapitler

1. The Skinny on GLP-1s for Healthcare Industry Risks (00:00:00)

2. Can you briefly explain what GLP-1 medications are and why their use is exploding right now? (00:02:03)

3. Walk us through some of the key risks for healthcare providers that are jumping into the GLP-1 fray. (00:03:32)

4. We’ve seen some FDA advisories around compounded versions of GLP-1s. How do you see this impacting providers? (00:04:38)

5. Are insurers pulling back? (00:06:00)

6. Do you anticipate litigation becoming a bigger concern for healthcare providers? (00:08:38)

7. What steps should healthcare providers be taking right now to mitigate these risks? (00:10:47)

8. Why is Team CRC the right partner? (00:18:41)

9. Rapid Fire! (00:20:36)